Limbach Holdings' Q3 Call Is Sitting in LeMaitre's Filing Cabinet

Limbach Holdings' Q3 Call Is Sitting in LeMaitre's Filing Cabinet

Something is wrong with the package. The earnings call provided for this report opens with "Limbach Holdings Third Quarter 2026 Earnings Conference Call," features CEO Mike McCann and CFO Jayme Brooks, and discusses record revenue of $230.5 million, a 1.4x book-to-bill, and acquisitions named CYMCOR and 1901. The company metadata says LeMaitre Vascular, a $1.84 billion medical-device maker. The prior five calls are LeMaitre calls: George LeMaitre, Dorian LeBlanc, Artegraft, cardiac allografts, pricing floors. The fundamentals are LeMaitre's: $70 million of quarterly revenue and a 72.1% gross margin. The tape is LMAT: a $117.39 April peak, now 25% below it.

This is not a company pivot. It is a data-integrity failure. And it matters because a dossier that pretends the Limbach transcript is a LeMaitre report would be fiction. So the honest story is twofold: what the Limbach call actually says, and what the LeMaitre record says that the call does not.

What the Limbach Call Actually Says

Limbach's Q3 was a return-to-growth quarter after a soft first half. Revenue was a record $230.5 million, up from $184.6 million a year ago. “Total organic growth was 6.6%, including 2.2% in ODR.” — Jayme Brooks, Executive Vice President and Chief Financial Officer · 2026-11-04 The owner-direct recovery is the key operating variable. “We saw a return to organic growth in our owner-direct business during the third quarter,” — Michael McCann, President and Chief Executive Officer · 2026-11-04 McCann said, adding that customers were working through budget decisions and timing issues discussed in Q2.

Bookings were the strongest evidence: $311 million, a 1.4x book-to-bill, the fourth consecutive quarter above 1.0x. “Bookings totaled approximately $311 million, producing a book-to-bill ratio of approximately 1.4x, representing a fourth consecutive quarter of favorable bookings to revenue.” — Michael McCann, President and Chief Executive Officer · 2026-11-04 That is the operational turnaround story. The company is tracking at or near the high end of revenue and adjusted-EBITDA guidance, but it did not raise the range because Q4 is still in progress.

The strategic additions are CYMCOR, a program-management and commissioning firm that gives Limbach earlier visibility into mission-critical projects including data center work, and 1901, a Wisconsin electrical contractor. McCann was careful on data centers: "Our approach is to be selective." The company wants scopes with "attractive economics and manageable risk," not volume for its own sake. It also has fabrication capacity that can support selected data-center packages, and it wants to bridge from day-one construction to day-two service and maintenance. The data-center thread is not unique to Limbach; it is a global theme echoed by semiconductor and hardware reporters in the recent earnings list.

Cash generation was strong. “For the first 9 months, operating cash flow was $31.2 million, and the company-defined free cash flow was $43.6 million, representing 87.1% of adjusted EBITDA.” — Jayme Brooks, Executive Vice President and Chief Financial Officer · 2026-11-04 Liquidity was $164.2 million after the two acquisitions, net debt was about 1.6x trailing adjusted EBITDA, and the company repurchased nearly 200,000 shares at an average of $51.31 for about $10 million.

We reviewed customer activity, project schedules and expected margins. We wanted our view of the year to reflect how the business is progressing at that moment, not simply the opportunity ahead.

That is a credible building-systems call. It is not a LeMaitre call.

The LeMaitre Record That Isn't Here

The prior LeMaitre calls are about a completely different operating model. In August, George LeMaitre was discussing Cardiac allografts growing 39% quarter-over-quarter, price floored products representing 55% of North American revenue, and the Artegraft OUS launch targeting $10 million for the year. He said: “There's an explosion of gross margin going on over in Europe.” — George LeMaitre, Chief Executive Officer · 2026-08-04 On the same call, he acknowledged the Quick Stick regulatory path: “We're not really a clinical trial company historically, but we do have these aspirations to get a little bit more R&D focused.” — George LeMaitre, Chief Executive Officer · 2026-08-04 None of that appears in the Limbach transcript.

The fundamentals confirm the mismatch. The provided LeMaitre data shows $70 million of quarterly revenue and a 72.1% gross margin. Limbach's transcript reports $230.5 million of revenue and a 23.4% gross margin. Those cannot be the same company. The tape is LMAT: a $1.84 billion market cap, down 25.1% from its April 14 peak of $117.39, and down 8.4% over the last 90 days. That is a LeMaitre tape, not a Limbach tape.

The keyword trajectory tells the same story. The current-quarter list is Limbach-specific: CYMCOR, "Limbach," "Jayme," "GCR work," "fabrication capacity." The prior quarter's list is LeMaitre-specific: "Cardiac allografts," "Artegraft sale," "German surgeons," "pricing floor." The knowledge base has been spliced.

Why It Matters

If you were handed this package and told "LeMaitre reported," you might build a thesis around the wrong numbers. The Limbach call has a genuine micro-story: a building-systems company recovering owner-direct growth, stacking book-to-bill, and using M&A to add data-center and electrical capability. The LeMaitre record has a different genuine story: a high-margin vascular-device company riding Artegraft in Europe, defending pricing floors, and managing allograft supply. Both can be interesting. They cannot be the same report.

The right conclusion is not to force a LeMaitre narrative onto Limbach's transcript. It is to flag the mismatch and wait for the correct transcript. Until then, the only defensible statement is that the Limbach Q3 call shows a return to organic growth and strong bookings, while the LeMaitre context shows a medical-device company with a 72% gross margin and a stock in a 25% drawdown. The two datasets should not be mixed.